The Clorox Company
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at The Clorox Company.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 84.90 $ to 127.20 $ · Last price: 85.00 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Household & Personal Products
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| The Clorox Company CLX | 10.3 | 14.2 | 13.9 | 42.3 | 17.0 | 0.2 | -29.1 |
| Procter & Gamble Company PG | 346.0 | 22.1 | 14.9 | 50.9 | 23.1 | 0.3 | -5.3 |
| Colgate-Palmolive Company CL | 70.6 | 35.0 | 19.7 | 60.4 | 20.9 | 1.4 | 9.4 |
| Estee Lauder Companies Inc EL | 34.0 | – | 25.1 | 75.5 | 14.9 | -8.5 | 8.0 |
| Kenvue Inc. KVUE | 33.3 | 21.5 | 13.0 | 58.4 | 21.6 | -2.1 | 3.1 |
| Kimberly-Clark Corporation KMB | 32.6 | 19.3 | 12.0 | 37.6 | 19.7 | -14.2 | -17.5 |
| Church & Dwight Company Inc CHD | 22.5 | 31.9 | 18.7 | 45.6 | 20.2 | 1.6 | 4.7 |
| ELF Beauty Inc ELF | 5.5 | 213.6 | 28.0 | 71.6 | 1.7 | 24.6 | -36.1 |
| Inter Parfums Inc IPAR | 3.5 | 20.9 | 11.7 | 58.4 | 21.5 | 2.5 | 10.6 |
| Median of companies shown | 32.6 | 21.8 | 14.9 | 58.4 | 20.2 | 0.3 | 3.1 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 5,973 | 1,117 | 701 | 5.33 | 868 | 542 | 4,573 |
| 2018 | 6,124 | 1,125 | 823 | 6.25 | 974 | 726 | 5,060 |
| 2019 | 6,214 | 1,107 | 820 | 6.32 | 992 | 559 | 5,116 |
| 2020 | 6,721 | 1,261 | 939 | 7.35 | 1,546 | 908 | 6,213 |
| 2021 | 7,341 | 1,225 | 710 | 5.58 | 1,276 | 592 | 6,334 |
| 2022 | 7,107 | 719 | 462 | 3.73 | 786 | 729 | 6,158 |
| 2023 | 7,389 | 823 | 149 | 1.20 | 1,158 | 388 | 5,945 |
| 2024 | 7,093 | 723 | 280 | 2.24 | 695 | 492 | 5,751 |
| 2025 | 7,104 | 1,177 | 810 | 6.52 | 981 | 482 | 5,561 |
| 2026 | 6,720 | 1,662 | 587 | 4.81 | 612 | 90 | 7,794 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.55 | 107.50 | 1,686 | -15.30 | 11.40 | 180 | 127 |
| 2025: Q1 | 1.50 | – | 1,668 | -8.00 | 11.20 | 286 | 233 |
| 2025: Q2 | 2.68 | 55.30 | 1,988 | 4.50 | 16.70 | 294 | 219 |
| 2025: Q3 | 0.65 | -18.10 | 1,429 | -18.90 | 5.60 | 93 | 57 |
| 2025: Q4 | 1.29 | -16.80 | 1,673 | -0.80 | 9.40 | 311 | 269 |
| 2026: Q1 | 1.54 | 2.40 | 1,670 | 0.10 | 11.20 | -122 | -165 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Aktien.Guide
Breakout & Setup
Momentum & Trend
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 06/30/2027 | 5.79 | 5.55 – 5.89 | 7,630 | 4.7% | 19 |
| 06/30/2028 | 6.26 | 5.80 – 6.57 | 7,812 | 8.1% | 18 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 10.9% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $405.0M |
|---|---|
| Market cap | $10.28B |
| Free cash flow in year ten | $1.14B |
| Terminal value as a share of market value | 58.7% |
For comparison: over the past five years free cash flow shrank by 15.6% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -3.1%
- More than 10% revenue growth is expected for the coming year 13.4%
- Share count grows by less than 3% a year -0.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 0.6%
- Gross margin at 40% or higher and without meaningful erosion 42.3%
- Goodwill from acquisitions does not grow faster than revenue 25.0%
- Net debt below twice EBITDA 5.8 x EBITDA
- Operating cash flow covers the profits of the last three years 611 m
- Return on capital at 15% or higher, or up versus two years ago 33.1%
- Insiders hold at least 10% or are net buyers 0.7%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
7/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 1.3%
- Exp. sales growth 3Y > 5% 7.8%
- EBIT growth 10Y > 5% 4.5%
- Exp. EBIT growth 3Y > 5% 14.1%
- Net debt < 4x EBIT 3.2x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 43.0%
- Return on equity > 15% –
- ROCE > 15% 33.1%
- Expected return > 10% 18.6%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 22, 2026 | Barton Nina | EVP-Chief Growth & Strategy Of | Other | 1,681 | 95.69 | 160,855 |
| Jul 15, 2026 | Hyder Chris T | EVP-Chief Operating Officer | Other | 277 | 94.75 | 26,246 |
The company
About the Company
The Clorox Company fertigt und vermarktet weltweit Verbraucher- und Profiprodukte. Das Unternehmen ist in vier Segmenten tätig: Health and Wellness, Household, Lifestyle und International.
- Employees
- 9,200
- Headquarters
- Oakland, CA
- Address
- 1221 Broadway, 94612-1888 Oakland, United States
- Phone
- 510 271 7000
- Website
- thecloroxcompany.com
- IPO Date
- 03/21/1983
- ISIN
- US1890541097
- Stock Split
- 2:1 on 08/24/1999
- Stock Split
- 2:1 on 09/03/1997
- Stock Split
- 2:1 on 06/02/1987
Management
| Name | Title | Birth Year |
|---|---|---|
| Linda J. Rendle | CEO & Chairman | 1978 |
| Luc Bellet | Executive VP & CFO | 1979 |
| Chris T. Hyder | Executive VP & COO | 1975 |
| Nina Barton | Executive VP and Chief Growth & Strategy Officer | 1974 |
| Laura E. Peck | VP, Chief Accounting Officer & Corporate Controller | 1977 |
| Chau Banks | Senior VP and Chief Information & Data Officer | 1969 |
| Kirsten M. Marriner | Executive VP & Chief Administrative Officer | 1973 |
| Lisah Burhan | Vice President of Investor Relations | – |
| Angela C. Hilt | Executive VP, Chief Legal & External Affairs Officer and Corporate Secretary | 1972 |
| Eric Sean Schwartz | Senior VP & Chief Marketing Officer | 1972 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/03/2026 CLOROX CO /DE/ (CLX): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.